EMA Accepts Otarmeni Gene Therapy for OTOF-Related Hearing Loss for Review
If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.
If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.
Research in children treated for the brain tumor ependymoma finds severe hearing loss is associated with worse intellectual ability and highlights the need for hearing interventions.
The therapy targets mutations in the CLIC5 gene, which affect hair cell stability and lead to progressive hearing and balance impairments.
A look at what we now know about how COVID-19 has been found to affect the auditory system, based on a review of the literature.
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
Understanding how and why people react to background noise could help in finding effective intervention strategies.
Researchers have developed a novel vibration-based technique to more accurately diagnose balance disorders like Meniere’s disease, especially in aging adults.